Reprint

Atherosclerotic and Cardiometabolic Disease: From Molecular Basis to Therapeutic Advances

Edited by
September 2023
292 pages
  • ISBN978-3-0365-8603-8 (Hardback)
  • ISBN978-3-0365-8602-1 (PDF)

This book is a reprint of the Special Issue Atherosclerotic and Cardiometabolic Disease: From Molecular Basis to Therapeutic Advances that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

In recent years, important progress has been made in the field of molecular biology concerning atherogenesis. However, there are still gaps in current knowledge regarding its underlying pathogenesis. Moreover, various diseases, such as non-alcoholic fatty liver disease/steatohepatitis, diabetes mellitus, arterial hypertension, dyslipidemia, and metabolic syndrome, are tightly connected with atherosclerosis, sharing, at least in part, common molecular pathogenetic mechanisms.Although cardiovascular diseases (CVDs) still remain the leading cause of death globally, lifestyle modification interventions, as well as pharmacological therapies (e.g., anti-hypertensive, lipid-lowering drugs) and advances in cardiovascular surgery, have led to a reduction in CVD mortality.This reprint of a Special Issue aims to provide new data and discuss recent advances in the field of atherosclerosis and atherosclerosis-related diseases. An improved understanding of the common pathophysiological processes that result in cardio-metabolic diseases will help in the identification of effective prevention strategies and the development of innovative therapeutic targets which can be introduced in routine clinical practice.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
critical limb ischemia; endothelial progenitor cells; nude mice; angiogenesis; hyperbaric oxygen therapy; coronary artery disease; epicardial adipose tissue; inflammation; cytokines; type 2 diabetes; SGLT2i; glucose metabolism; insulin resistance; atherosclerosis; heart failure; soluble suppression of tumorigenesis-2; endothelial function; FMD; cardiometabolic risk; incretin system; dipeptidyl peptidase 4; sodium-glucose-co-transporter 2 inhibitors; proprotein convertase subtilisin kexin 9; NAFLD; SGLT-2 inhibitors; autophagy; ER stress; apoptosis; inflammation; atherosclerosis; carotid plaque; coronary artery disease; inflammation; oxidative stress; sestrin2; atherosclerotic plaque; stabilization; vulnerable plaque; inflammation; macrophage; intravascular ultrasound; myocardial infarction; necrotic cores; cell death; atrial fibrillation; pathogenesis; oxidative stress; predisposing factors; diets; Mediterranean diet; genetics; non-alcoholic fatty liver disease; NAFLD; MAFLD; SGLT-2; sodium-glucose co-transporter type-2 inhibitors; metabolic syndrome; coronary artery ectasia; coronary artery aneurysm; CAD; cytokine; lipidome; coronary atherosclerosis; computed tomography coronary angiography; genes; protein; trace element; atherosclerosis; plaque vulnerability; estrogen; estrogen receptors; GPR-30; endothelial cells; matrix metalloproteinases MMPs; MCP-1; p21; non-alcoholic fatty liver disease; NAFLD; non-alcoholic steatohepatitis; NASH; animal models; mouse; cirrhosis; n/a